EFFECT OF PNEUMOCOCCAL CONJUGATE VACCINE ON THE LENGTH OF HOSPITALIZATION IN CHILDREN UNDER FIVE WITH PNEUMONIA IN BURKINA FASO

Background Pneumococcus is a leading cause of childhood morbidity and mortality worldwide. We assessed the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on the hospitalization length among children under five years hospitalized for pneumonia in Burkina Faso.

We conducted a secondary analysis of data collected from hospitalized pneumonia cases participating in a diagnostic validation study between December 2015 and January 2017. A Cox proportional hazards model was used to assess the association between vaccination status and time to discharge.

A total of 280 children were included, of whom 187 (66.8%) had received three PCV13 doses. The mean hospitalization duration was 7.99 days (95% CI 7.17–8.81) for those fully vaccinated vs. 10.44 days (95% CI 9.07–11.80) among children with <3 doses. Full vaccination was associated with a significantly higher recovery rate (aHR: 1.45; 95% CI: 1.11–2.08, p = 0.01).

PCV13 significantly reduces hospitalization length due to pneumonia among children under five in Burkina Faso. Competing Interest Statement The authors have declared no competing interest. Funding Statement This study was financially supported by Pfizer. The funder had no role in study design, data collection, analysis, interpretation, decision to publish, or preparation of the manuscript Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study protocol was approved by the Burkina Faso Health Research Ethics Committee (Approval No. 2015-5-064, May 6, 2015). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes